Lipase News and Research

RSS
Synageva supports Fourth International Rare Disease Day

Synageva supports Fourth International Rare Disease Day

AMT 2010 total net income increases to EUR 1.4 million

AMT 2010 total net income increases to EUR 1.4 million

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

New mouse model with deficiency of lipoprotein lipase in neurons

New mouse model with deficiency of lipoprotein lipase in neurons

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Angptl4 protein deficiency could promote inflammatory response in people who consume high saturated fat

Angptl4 protein deficiency could promote inflammatory response in people who consume high saturated fat

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva receives $2.3 million under QTDP program

Synageva receives $2.3 million under QTDP program

Injecting apoA-V protein may reduce high triglyceride levels: Research

Injecting apoA-V protein may reduce high triglyceride levels: Research

Progenika receives CE Mark approval to market LPLchip in Europe

Progenika receives CE Mark approval to market LPLchip in Europe

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular first half 2010 net loss in line with last year

Continuous boosting of natural painkiller shuts down brain cell receptor response

Continuous boosting of natural painkiller shuts down brain cell receptor response

AMT's MAA for LPLD gene therapy product Glybera on schedule

AMT's MAA for LPLD gene therapy product Glybera on schedule

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

Survey links autism with digestive problems, intestinal inflammation

Survey links autism with digestive problems, intestinal inflammation

New findings show why some people suffer from high levels of triglycerides

New findings show why some people suffer from high levels of triglycerides

FDA grants orphan drug designation for Synageva BioPharma's SBC-102

FDA grants orphan drug designation for Synageva BioPharma's SBC-102

Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase

Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase